Introduction: Abnormalities in immune function have been described in schizophrenia. Cytokines, key signaling molecules of the immune system, have been investigated in peripheral blood samples of patients with schizophrenia though few studies have investigated cytokines in cerebrospinal fluid (CSF). Moreover, very few studies with schizophrenia subjects have investigated the relationships between CSF and blood cytokine levels or investigated sex differences. Methods: In this cross-sectional study, subjects with schizophrenia spectrum disorder (SSD) diagnosis and healthy volunteers (HV) underwent a lumbar puncture, a blood draw, and psychopathology ratings. CSF and plasma levels of IL-1B, IL-2, IL-4, IL-6, IL-8 and TNFα; were determined by enzyme-linked immunosorbent assay (ELISA) and a high-sensitivity MilliplexTM Multiplex kit. Cytokine levels were square root transformed and compared between both groups using bivariate tests and a multivariate regression analysis. CSF and plasma cytokine levels were compared as were the effects of sex. Results: Thirty SSD and 23 HV were included in the study. In bivariate analysis, CSF TNFα; and IL-4 levels were significantly increased in SSD subjects compared to HV. Multivariate regression analysis also showed increases in TNFα; and IL-4 after adjusting for sex, age and body mass index. There were no significant differences in plasma cytokine levels between groups, and there were no correlations between CSF and plasma cytokine levels. CSF levels of TNFα; and IL-4 were negatively correlated with speed of processing. Stratified analysis by sex showed significantly increased levels of TNFα; and IL-4 in SSD vs. HV in males but not in females, although sample sizes were small after stratification.

Drs. Gallego, Castaneda, Jimenez, Alvarez-Lesmes and Lencz have nothing to disclose. Emily Blanco has nothing to disclose. Dr. Malhotra is a consultant to Genomind Inc and InformedDNA,

This study was supported in part by a NARSAD Young Investigator Grant (PI: J. Gallego) from the Brain & Behavior Research Foundation, a K23MH100264 from the National Institute of Mental Health (PI: J. Gallego), and R01DK097599 (PI: McNamara). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Brain & Behavior Research Foundation.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All subjects provided written informed consent to a protocol approved by the Institutional Review Board of the Northwell Health System

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors